broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5 | ACH-000996 | HEC251_ENDOMETRIUM | HTS002 | 1 | 1.66413 | -0.179775 | -0.059451 | 1.142037 | 0.000038 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000996 |
BRD-K71847383-001-12-5 | ACH-000622 | KNS42_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.388223 | -0.147598 | 0.015874 | 1.182435 | 0.033369 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000622 |
BRD-K71847383-001-12-5 | ACH-000403 | NCIH747_LARGE_INTESTINE | HTS002 | 1 | 1.341018 | 0.245988 | -0.203967 | 1.230065 | 0.002902 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000403 |
BRD-K71847383-001-12-5 | ACH-000141 | SNU308_BILIARY_TRACT | HTS002 | 1 | 2.19792 | -0.246082 | 0.110336 | 1.314495 | 0.000752 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000141 |
BRD-K71847383-001-12-5 | ACH-000988 | MFE319_ENDOMETRIUM | HTS002 | 1 | 1.417748 | -0.75312 | 0.141324 | 1.094296 | 0.004129 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000988 |
BRD-K71847383-001-12-5 | ACH-000848 | JHH7_LIVER | HTS002 | 1 | 1.608422 | -0.290429 | 0.135529 | 1.327401 | 0.143795 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000848 |
BRD-K71847383-001-12-5 | ACH-000785 | NCIH2126_LUNG | HTS002 | 1 | 1.858508 | -0.622198 | 0.131908 | 1.32144 | 0.020083 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000785 |
BRD-K71847383-001-12-5 | ACH-000544 | OE21_OESOPHAGUS | HTS002 | 1 | 1.524409 | 1.061857 | 0.004385 | 1.449052 | 0.001931 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000544 |
BRD-K71847383-001-12-5 | ACH-000982 | GP2D_LARGE_INTESTINE | HTS002 | 1 | 2.067322 | -0.454984 | -0.056182 | 1.278291 | 0.00362 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000982 |
BRD-K71847383-001-12-5 | ACH-000021 | NCIH1693_LUNG | HTS002 | 1 | 1.09997 | -0.088182 | -0.026476 | 1.059635 | 7.037291 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000021 |
BRD-K71847383-001-12-5 | ACH-000823 | KYSE140_OESOPHAGUS | HTS002 | 1 | 1.45618 | -0.290212 | -0.062462 | 1.138347 | 0.002887 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000823 |
BRD-K71847383-001-12-5 | ACH-000984 | HEC6_ENDOMETRIUM | HTS002 | 1 | 1.630324 | 0.603439 | -0.068629 | 1.364856 | 0.033217 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000984 |
BRD-K71847383-001-12-5 | ACH-000579 | UACC257_SKIN | HTS002 | 1 | 1.890047 | -0.091725 | 0.049193 | 1.418633 | 0.020957 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000579 |
BRD-K71847383-001-12-5 | ACH-001306 | 8305C_THYROID | HTS002 | 1 | 1.608385 | 4.061808 | 0.12486 | 1.16195 | 0.755328 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001306 |
BRD-K71847383-001-12-5 | ACH-000318 | TE10_OESOPHAGUS | HTS002 | 1 | 1.919951 | -0.048864 | -0.010108 | 1.437761 | 0.010706 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000318 |
BRD-K71847383-001-12-5 | ACH-000840 | HCC366_LUNG | HTS002 | 1 | 1.204166 | 1.16225 | -0.100847 | 1.138097 | 0.013795 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000840 |
BRD-K71847383-001-12-5 | ACH-000503 | BICR16_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 9.353365 | -2.558364 | 0.288094 | 1.069258 | 0.000343 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000503 |
BRD-K71847383-001-12-5 | ACH-000919 | IM95_STOMACH | HTS002 | 1 | 2.86146 | 0.285706 | 0.024343 | 1.251864 | 112.569045 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000919 |
BRD-K71847383-001-12-5 | ACH-000822 | SKMEL24_SKIN | HTS002 | 1 | 1.705546 | -0.267401 | 0.040914 | 1.302584 | 0.023145 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000822 |
BRD-K71847383-001-12-5 | ACH-000292 | NCIH841_LUNG | HTS002 | 1 | 1.936598 | -0.246336 | 0.138943 | 1.330773 | 0.005078 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000292 |
BRD-K71847383-001-12-5 | ACH-000827 | WM793_SKIN | HTS002 | 1 | 1.34756 | -1.350708 | 0.190575 | 1.215558 | 0.25206 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000827 |
BRD-K71847383-001-12-5 | ACH-000411 | 769P_KIDNEY | HTS002 | 1 | 1.355958 | -0.809507 | 0.226213 | 1.264768 | 0.990264 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000411 |
BRD-K71847383-001-12-5 | ACH-000139 | PANC0327_PANCREAS | HTS002 | 1 | 0.924605 | 0.568325 | -0.201794 | 0.937375 | 0.001336 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000139 |
BRD-K71847383-001-12-5 | ACH-000569 | ISTMES1_PLEURA | HTS002 | 1 | 2.089649 | -0.487809 | 0.085823 | 1.194269 | 0.001135 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000569 |
BRD-K71847383-001-12-5 | ACH-000278 | COV362_OVARY | HTS002 | 1 | 1.219204 | -0.07241 | -0.002248 | 1.096558 | 0.002778 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000278 |
BRD-K71847383-001-12-5 | ACH-000425 | UACC62_SKIN | HTS002 | 1 | 1.661403 | 0.081608 | -0.022341 | 1.310153 | 0.366081 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000425 |
BRD-K71847383-001-12-5 | ACH-000013 | ONCODG1_OVARY | HTS002 | 1 | 2.305866 | 0.110774 | -0.160194 | 1.401125 | 142.577303 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000013 |
BRD-K71847383-001-12-5 | ACH-000730 | SKMEL5_SKIN | HTS002 | 1 | 1.513883 | 0.077037 | -0.02417 | 1.33272 | 0.000027 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000730 |
BRD-K71847383-001-12-5 | ACH-000500 | SNU46_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.849929 | -0.417057 | 0.010547 | 1.122608 | 0.000378 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000500 |
BRD-K71847383-001-12-5 | ACH-000222 | ASPC1_PANCREAS | HTS002 | 1 | 1.128642 | 0.483312 | -0.098323 | 1.077165 | 0.023894 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000222 |
BRD-K71847383-001-12-5 | ACH-000477 | MALME3M_SKIN | HTS002 | 1 | 1.74188 | -0.159639 | 0.071407 | 1.272825 | 0.002225 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000477 |
BRD-K71847383-001-12-5 | ACH-000223 | HCC1937_BREAST | HTS002 | 1 | 1.20395 | 0.345411 | -0.128653 | 1.156517 | 0.001242 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000223 |
BRD-K71847383-001-12-5 | ACH-000495 | TUHR4TKB_KIDNEY | HTS002 | 1 | 1.418975 | 0.158799 | -0.043352 | 1.287589 | 0.000447 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000495 |
BRD-K71847383-001-12-5 | ACH-000434 | NCIH1915_LUNG | HTS002 | 1 | 1.628387 | -0.45208 | 0.2583 | 1.160206 | 0.00329 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000434 |
BRD-K71847383-001-12-5 | ACH-000744 | NCIH1623_LUNG | HTS002 | 1 | 1.143532 | -0.089125 | -0.093594 | 1.079561 | 0.937549 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000744 |
BRD-K71847383-001-12-5 | ACH-000107 | CAPAN2_PANCREAS | HTS002 | 1 | 1.710207 | -0.043703 | 0.015375 | 1.327933 | 0.002309 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000107 |
BRD-K71847383-001-12-5 | ACH-000516 | CAL78_BONE | HTS002 | 1 | 1.516738 | -0.430137 | -0.010011 | 1.151969 | 0.005363 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000516 |
BRD-K71847383-001-12-5 | ACH-000182 | SNU869_BILIARY_TRACT | HTS002 | 1 | 1.944138 | -0.444945 | 0.150753 | 1.24563 | 0.003459 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000182 |
BRD-K71847383-001-12-5 | ACH-000898 | SNU719_STOMACH | HTS002 | 1 | 1.961284 | -0.576289 | 0.060378 | 1.220208 | 0.003281 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000898 |
BRD-K71847383-001-12-5 | ACH-000040 | U118MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.673846 | -0.163182 | -0.044388 | 1.403579 | 1.033555 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000040 |
BRD-K71847383-001-12-5 | ACH-000808 | HUH28_BILIARY_TRACT | HTS002 | 1 | 1.608876 | -0.080285 | -0.062346 | 1.276792 | 0.007857 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000808 |
BRD-K71847383-001-12-5 | ACH-000447 | NCIH2228_LUNG | HTS002 | 1 | 1.136011 | 0.009563 | -0.111553 | 1.053976 | 808,472,476,761,998,500 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000447 |
BRD-K71847383-001-12-5 | ACH-000715 | SNU1214_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 2.09 | -0.179554 | -0.024437 | 1.247867 | 0.000059 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000715 |
BRD-K71847383-001-12-5 | ACH-000186 | NCIH2444_LUNG | HTS002 | 1 | 1.477806 | -0.900742 | -0.041205 | 1.251487 | 0.101544 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000186 |
BRD-K71847383-001-12-5 | ACH-000542 | HEYA8_OVARY | HTS002 | 1 | 1.765968 | -0.16546 | -0.184065 | 1.414989 | 0.226891 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000542 |
BRD-K71847383-001-12-5 | ACH-000943 | RKO_LARGE_INTESTINE | HTS002 | 1 | 1.151696 | 0.120367 | -0.000016 | 1.096412 | 0.000677 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000943 |
BRD-K71847383-001-12-5 | ACH-000174 | CAL62_THYROID | HTS002 | 1 | 1.496954 | -0.679237 | 0.691334 | 1.192906 | 0.024067 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000174 |
BRD-K71847383-001-12-5 | ACH-000393 | HLF_LIVER | HTS002 | 1 | 2.492667 | -0.145572 | 0.07608 | 1.61281 | 0.005884 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000393 |
BRD-K71847383-001-12-5 | ACH-000018 | T24_URINARY_TRACT | HTS002 | 1 | 1.831768 | -0.263074 | 0.049117 | 1.295094 | 0.00601 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000018 |
BRD-K71847383-001-12-5 | ACH-000906 | ES2_OVARY | HTS002 | 1 | 1.487635 | -0.743258 | -0.338532 | 1.281069 | 0.171282 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000906 |
BRD-K71847383-001-12-5 | ACH-000784 | KYSE70_OESOPHAGUS | HTS002 | 1 | 3.468248 | -0.454166 | 0.015226 | 1.315094 | 0.000345 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000784 |
BRD-K71847383-001-12-5 | ACH-000265 | KP4_PANCREAS | HTS002 | 1 | 2.115068 | -0.0738 | -0.037106 | 1.548068 | 0.04907 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000265 |
BRD-K71847383-001-12-5 | ACH-000880 | AGS_STOMACH | HTS002 | 1 | 1.323669 | 0.079653 | -0.01807 | 1.168073 | 0.029309 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000880 |
BRD-K71847383-001-12-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | HTS002 | 1 | 1.635233 | -4.698613 | 0.805178 | 1.229801 | 0.020426 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000961 |
BRD-K71847383-001-12-5 | ACH-000847 | HGC27_STOMACH | HTS002 | 1 | 1.107848 | -0.078207 | -0.303913 | 1.060393 | 1.768253 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000847 |
BRD-K71847383-001-12-5 | ACH-000896 | 647V_URINARY_TRACT | HTS002 | 1 | 1.424256 | 0.073293 | -0.012503 | 1.234028 | 0.004488 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000896 |
BRD-K71847383-001-12-5 | ACH-000685 | L33_PANCREAS | HTS002 | 1 | 1.602589 | -2.121454 | 0.087234 | 1.500916 | 1.974056 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000685 |
BRD-K71847383-001-12-5 | ACH-000376 | SF295_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.179642 | -0.133328 | -0.27156 | 1.130573 | 152.421845 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000376 |
BRD-K71847383-001-12-5 | ACH-000428 | UO31_KIDNEY | HTS002 | 1 | 2.200919 | -0.771553 | -0.108107 | 1.025789 | 0.000064 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000428 |
BRD-K71847383-001-12-5 | ACH-000749 | DMS273_LUNG | HTS002 | 1 | 2.024865 | 0.082546 | -0.082323 | 1.617646 | 0.00047 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000749 |
BRD-K71847383-001-12-5 | ACH-000572 | G361_SKIN | HTS002 | 1 | 1.968091 | -0.417417 | 0.239501 | 1.292916 | 0.005791 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000572 |
BRD-K71847383-001-12-5 | ACH-000457 | CAL54_KIDNEY | HTS002 | 1 | 1.123728 | 0.058488 | -0.00677 | 1.060945 | 0.130323 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000457 |
BRD-K71847383-001-12-5 | ACH-000601 | MIAPACA2_PANCREAS | HTS002 | 1 | 1.580652 | -0.028907 | 0.035399 | 1.284154 | 0.0179 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000601 |
BRD-K71847383-001-12-5 | ACH-000651 | SW620_LARGE_INTESTINE | HTS002 | 1 | 1.527829 | -0.540686 | 0.185064 | 1.273207 | 0.095193 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000651 |
BRD-K71847383-001-12-5 | ACH-000361 | SKHEP1_LIVER | HTS002 | 1 | 1.409461 | -0.183088 | 0.108342 | 1.21608 | 0.14898 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000361 |
BRD-K71847383-001-12-5 | ACH-000842 | SW480_LARGE_INTESTINE | HTS002 | 1 | 1.594244 | -0.359648 | 0.162307 | 1.172461 | 0.003713 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000842 |
BRD-K71847383-001-12-5 | ACH-000570 | YKG1_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 2.17355 | 0.061479 | -0.154803 | 1.550919 | 0.580217 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000570 |
BRD-K71847383-001-12-5 | ACH-000396 | J82_URINARY_TRACT | HTS002 | 1 | 1.167856 | 0.144567 | -0.076571 | 1.069891 | 0.887262 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000396 |
BRD-K71847383-001-12-5 | ACH-000777 | KYSE30_OESOPHAGUS | HTS002 | 1 | 1.780203 | -0.35144 | 0.260077 | 1.278052 | 0.009969 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000777 |
BRD-K71847383-001-12-5 | ACH-000096 | G401_SOFT_TISSUE | HTS002 | 1 | 1.648856 | -0.377861 | 0.112391 | 1.217019 | 0.007959 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000096 |
BRD-K71847383-001-12-5 | ACH-000955 | SNU407_LARGE_INTESTINE | HTS002 | 1 | 2.549763 | -0.348491 | 0.189183 | 1.797917 | 0.096331 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000955 |
BRD-K71847383-001-12-5 | ACH-000940 | AN3CA_ENDOMETRIUM | HTS002 | 1 | 1.454095 | 0.02148 | -0.019772 | 1.245016 | 0.000048 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000940 |
BRD-K71847383-001-12-5 | ACH-001318 | PLCPRF5_LIVER | HTS002 | 1 | 1.623403 | -0.097543 | 0.017441 | 1.298966 | 0.033265 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001318 |
BRD-K71847383-001-12-5 | ACH-000332 | YAPC_PANCREAS | HTS002 | 1 | 1.444793 | 0.198488 | -0.022957 | 1.211098 | 0.135587 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000332 |
BRD-K71847383-001-12-5 | ACH-000839 | SCABER_URINARY_TRACT | HTS002 | 1 | 1.634617 | -0.622596 | -0.064978 | 1.122958 | 0.002231 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000839 |
BRD-K71847383-001-12-5 | ACH-000178 | HS766T_PANCREAS | HTS002 | 1 | 2.117962 | 0.138319 | 0.041361 | 1.549771 | 0.100026 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000178 |
BRD-K71847383-001-12-5 | ACH-000421 | SW837_LARGE_INTESTINE | HTS002 | 1 | 2.723479 | 0.255413 | -0.143096 | 1.225303 | 265.340885 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000421 |
BRD-K71847383-001-12-5 | ACH-000524 | KURAMOCHI_OVARY | HTS002 | 1 | 2.257968 | -0.397461 | 0.144219 | 1.489548 | 0.018151 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000524 |
BRD-K71847383-001-12-5 | ACH-000153 | NCIH2052_PLEURA | HTS002 | 1 | 1.417734 | 0.121546 | -0.043331 | 1.26227 | 0.000937 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000153 |
BRD-K71847383-001-12-5 | ACH-000805 | COLO679_SKIN | HTS002 | 1 | 1.993288 | -0.07495 | -0.125977 | 1.471299 | 0.019695 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000805 |
BRD-K71847383-001-12-5 | ACH-000429 | A704_KIDNEY | HTS002 | 1 | 0.975675 | 0.11513 | -0.215958 | 0.983198 | 0.000061 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000429 |
BRD-K71847383-001-12-5 | ACH-000108 | KP3_PANCREAS | HTS002 | 1 | 1.266956 | -3.329742 | 0.183945 | 1.177258 | 0.383661 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000108 |
BRD-K71847383-001-12-5 | ACH-000939 | SKUT1_SOFT_TISSUE | HTS002 | 1 | 1.548814 | -0.201182 | 0.107034 | 1.323542 | 0.542851 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000939 |
BRD-K71847383-001-12-5 | ACH-000323 | 42MGBA_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.655581 | -0.20409 | 0.055456 | 1.233443 | 0.003418 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000323 |
BRD-K71847383-001-12-5 | ACH-000219 | A375_SKIN | HTS002 | 1 | 1.461794 | -0.303079 | 0.310451 | 1.221613 | 0.057206 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000219 |
BRD-K71847383-001-12-5 | ACH-000054 | HT1080_SOFT_TISSUE | HTS002 | 1 | 1.128936 | -0.112964 | -0.02667 | 1.073308 | 0.955028 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000054 |
BRD-K71847383-001-12-5 | ACH-000302 | SNU1077_ENDOMETRIUM | HTS002 | 1 | 3.514349 | -0.247353 | -0.000334 | 1.372369 | 0.000034 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000302 |
BRD-K71847383-001-12-5 | ACH-000324 | JHOC5_OVARY | HTS002 | 1 | 1.39086 | -1.632562 | 0.21977 | 1.308182 | 1.312257 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000324 |
BRD-K71847383-001-12-5 | ACH-000164 | PANC1_PANCREAS | HTS002 | 1 | 1.314857 | -0.026872 | -0.037701 | 1.143519 | 0.000106 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000164 |
BRD-K71847383-001-12-5 | ACH-000549 | SNU1076_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.763049 | -0.218239 | 0.042705 | 1.289129 | 0.006623 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000549 |
BRD-K71847383-001-12-5 | ACH-000650 | IGR37_SKIN | HTS002 | 1 | 1.718212 | -0.221926 | -0.329949 | 1.321186 | 0.027465 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000650 |
BRD-K71847383-001-12-5 | ACH-000217 | JHH6_LIVER | HTS002 | 1 | 2.099282 | -0.154255 | -0.028402 | 1.362635 | 0.000644 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000217 |
BRD-K71847383-001-12-5 | ACH-000463 | NCIH460_LUNG | HTS002 | 1 | 1.398672 | 0.014835 | -0.058375 | 1.20806 | 0.000213 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000463 |
BRD-K71847383-001-12-5 | ACH-000748 | SJSA1_BONE | HTS002 | 1 | 1.472746 | -0.033403 | 0.000362 | 1.223345 | 0.002851 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000748 |
BRD-K71847383-001-12-5 | ACH-000788 | A2058_SKIN | HTS002 | 1 | 1.257768 | 0.083951 | -0.082503 | 1.139931 | 0.009808 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000788 |
BRD-K71847383-001-12-5 | ACH-000545 | VMCUB1_URINARY_TRACT | HTS002 | 1 | 1.230556 | -0.330321 | -0.069765 | 1.155792 | 1.114415 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000545 |
BRD-K71847383-001-12-5 | ACH-000762 | YD38_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.793875 | -0.086831 | -0.070986 | 1.394286 | 0.06683 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000762 |
BRD-K71847383-001-12-5 | ACH-000792 | BFTC909_KIDNEY | HTS002 | 1 | 3.423108 | -0.328087 | 0.188778 | 1.488262 | 0.000567 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000792 |
BRD-K71847383-001-12-5 | ACH-000211 | DAOY_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 2.524189 | 0.210277 | -0.019123 | 1.289017 | 128.817277 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000211 |
BRD-K71847383-001-12-5 | ACH-000936 | EFO27_OVARY | HTS002 | 1 | 1.547973 | 0.110772 | -0.013901 | 1.395708 | 0.000012 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000936 |